Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps
Volume: 62 - Issue: 3
First page: 383 - Last page: 384
R. van der Lans - J.J. Otten - G.F.J.P.M. Adriaensen - L.B.L. Benoist - M.E. Cornet - D.R. Hoven - A.B. Rinia - W.J. Fokkens - S. Reitsma
The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) defines markers for type2 inflammation in the context of indicating biological therapy in severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as either a total serum immunoglobulin E (total-IgE)
Rhinology 62-3: 383-384, 2024
To see the issue content and the abstract you do not have to login
Please login to download the full articles
If you do not have a subscription to Rhinology please consider taking one.
